Globitair

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Financial PostPeople's Republic of China

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical […]

Read the full story at Financial PostOpen in the live monitor

Related discussion groups

No group discusses this yet. Start a discussion group and attach this story.

More news about People's Republic of China